Peripheral blood mononuclear cells of patients with breast cancer can be reprogrammed to enhance anti-HER-2/neu reactivity and overcome myeloid-derived suppressor cells

Breast Cancer Research and Treatment

Volumn 142, Issue 1, 2013, Pages 45-57

  Payne, Kyle K ^a   Zoon, Christine K ^b   Wan, Wen ^a   Marlar, Khin ^c   Keim, Rebecca C ^a   Kenari, Mehrab Nasiri ^c   Kazim, A Latif ^c   Bear, Harry D ^b   Manjili, Masoud H ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Breast cancer; Cancer immunotherapy; Myeloid derived suppressor cells (MDSCs); NK cells; NKT cells

Indexed keywords

BRYOSTATIN 1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 7; IONOMYCIN; L SELECTIN; NATURAL KILLER CELL RECEPTOR NKG2D;

ARTICLE; BREAST CANCER; CELL EXPANSION; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; EX VIVO STUDY; HUMAN; HUMAN CELL; MEMORY T LYMPHOCYTE; MYELOID DERIVED SUPPRESSOR CELL; NATURAL KILLER CELL; NATURAL KILLER T CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PILOT STUDY; PRIORITY JOURNAL; SUPPRESSOR CELL;

BREAST NEOPLASMS; BRYOSTATINS; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-15; INTERLEUKIN-2; INTERLEUKIN-7; IONOMYCIN; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBSETS; MYELOID CELLS; NATURAL KILLER T-CELLS; NEOPLASM STAGING; RECEPTOR, ERBB-2; TUMOR BURDEN;

EID: 84888286401     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2733-5     Document Type: Article

References (58)

1. Sotomayor EM, Borrello I, Levitsky HI (1996) Tolerance and cancer: a critical issue in tumor immunology. Crit Rev Oncog 7:433-456
2. Guckel B, Rentzsch C, Nastke MD et al (2006) Pre-existing T-cell immunity against mucin-1 in breast cancer patients and healthy volunteers. J Cancer Res Clin Oncol 132:265-274
3. Goodell V, Waisman J, Salazar LG et al (2008) Level of HER-2/neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunity. Mol Cancer Ther 7:449-454
4. Rentzsch C, Kayser S, Stumm S et al (2003) Evaluation of pre-existent immunity in patients with primary breast cancer: molecular and cellular assays to quantify antigen-specific T lymphocytes in peripheral blood mononuclear cells. Clin Cancer Res 9:4376-4386
5. Morales JK, Kmieciak M, Knutson KL et al (2010) GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cells. Breast Cancer Res Treat 123:39-49
6. Ostrand-Rosenberg S (2010) Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother 59:1593-1600
7. Pastula A, Marcinkiewicz J (2011) Myeloid-derived suppressor cells: a double-edged sword? Int J Exp Pathol 92:73-78
8. Morales JK, Kmieciak M, Graham L et al (2009) Adoptive transfer of HER2/neu-specific T cells expanded with alternating gamma chain cytokines mediate tumor regression when combined with the depletion of myeloid-derived suppressor cells. Cancer Immunol Immunother 58:941-953
9. Dugast AS, Haudebourg T, Coulon F et al (2008) Myeloid-derived suppressor cells accumulate in kidney allograft tolerance and specifically suppress effector T cell expansion. J Immunol 180:7898-7906
10. Tuve S, Chen BM, Liu Y et al (2007) Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses. Cancer Res 67:5929-5939
11. Bernhard H, Neudorfer J, Gebhard K et al (2008) Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer. Cancer Immunol Immunother 57:271-280
12. Hong JJ, Rosenberg SA, Dudley ME et al (2010) Successful treatment of melanoma brain metastases with adoptive cell therapy. Clin Cancer Res 16:4892-4898
13. Rosenberg SA, Dudley ME, Restifo NP (2008) Cancer immunotherapy. N Engl J Med 359:1072
14. Hodi FS, O'Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723
15. Wolchok JD, Kluger H, Callahan MK et al (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369:122-133
16. Di Lorenzo G, Buonerba C, Kantoff PW (2011) Immunotherapy for the treatment of prostate cancer. Nat Rev Clin Oncol 8:551-561
17. Cantrell DA (1996) T cell antigen receptor signal transduction pathways. Cancer Surv 27:165-175
18. Chatila T, Silverman L, Miller R et al (1989) Mechanisms of T cell activation by the calcium ionophore ionomycin. J Immunol 143:1283-1289
19. Kazanietz MG, Lewin NE, Gao F et al (1994) Binding of [26-3H]bryostatin 1 and analogs to calcium-dependent and calcium-independent protein kinase C isozymes. Mol Pharmacol 46:374-379
20. Chin CS, Miller CH, Graham L et al (2004) Bryostatin 1/ionomycin (B/I) ex vivo stimulation preferentially activates L-selectinlow tumor-sensitized lymphocytes. Int Immunol 16:1283-1294
21. Tuttle TM, Inge TH, Wirt CP et al (1992) Bryostatin 1 activates T cells that have antitumor activity. J Immunother 12:75-81
22. Tan JT, Dudl E, LeRoy E et al (2001) IL-7 is critical for homeostatic proliferation and survival of naive T cells. Proc Natl Acad Sci USA 98:8732-8737
23. Tan JT, Ernst B, Kieper WC et al (2002) Interleukin (IL)-15 and IL-7 jointly regulate homeostatic proliferation of memory phenotype CD8+ cells but are not required for memory phenotype CD4+ cells. J Exp Med 195:1523-1532
24. Pillet AH, Bugault F, Theze J et al (2009) A programmed switch from IL-15- to IL-2-dependent activation in human NK cells. J Immunol 182:6267-6277
25. Gordy LE, Bezbradica JS, Flyak AI et al (2011) IL-15 regulates homeostasis and terminal maturation of NKT cells. J Immunol 187:6335-6345
26. Dai Z, Konieczny BT, Lakkis FG (2000) The dual role of IL-2 in the generation and maintenance of CD8+ memory T cells. J Immunol 165:3031-3036
27. Bessoles S, Fouret F, Dudal S et al (2008) IL-2 triggers specific signaling pathways in human NKT cells leading to the production of pro- and anti-inflammatory cytokines. J Leukoc Biol 84:224-233
28. de Lalla C, Festuccia N, Albrecht I et al (2008) Innate-like effector differentiation of human invariant NKT cells driven by IL-7. J Immunol 180:4415-4424
29. Rubinstein MP, Kovar M, Purton JF et al (2006) Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}. Proc Natl Acad Sci USA 103:9166-9171
30. Kmieciak M, Basu D, Payne KK et al (2011) Activated NKT cells and NK cells render T cells resistant to myeloid-derived suppressor cells and result in an effective adoptive cellular therapy against breast cancer in the FVBN202 transgenic mouse. J Immunol 187:708-717
31. Kmieciak M, Toor A, Graham L et al (2011) Ex vivo expansion of tumor-reactive T cells by means of bryostatin 1/ionomycin and the common gamma chain cytokines formulation. J Vis Exp pii:2381. doi: 10.3791/2381
32. Kmieciak M, Payne KK, Idowu MO et al (2011) Tumor escape and progression of HER-2/neu negative breast cancer under immune pressure. J Transl Med 9:35
33. Kmieciak M, Gowda M, Graham L et al (2009) Human T cells express CD25 and Foxp3 upon activation and exhibit effector/memory phenotypes without any regulatory/suppressor function. J Transl Med 7:89
34. Meier J, Roberts C, Avent K et al (2013) Fractal organization of the human T cell repertoire in health and after stem cell transplantation. Biol Blood Marrow Transplant 19:366-377
35. Ko HJ, Lee JM, Kim YJ et al (2009) Immunosuppressive myeloid-derived suppressor cells can be converted into immunogenic APCs with the help of activated NKT cells: an alternative cell-based antitumor vaccine. J Immunol 182:1818-1828
36. Lee JM, Seo JH, Kim YJ et al (2012) The restoration of myeloid-derived suppressor cells as functional antigen-presenting cells by NKT cell help and all-trans-retinoic acid treatment. Int J Cancer 131:741-751
37. Luft T, Pang KC, Thomas E et al (1998) Type I IFNs enhance the terminal differentiation of dendritic cells. J Immunol 161:1947-1953
38. Zhang Y, Harada A, Wang JB et al (1998) Bifurcated dendritic cell differentiation in vitro from murine lineage phenotype-negative c-kit+ bone marrow hematopoietic progenitor cells. Blood 92:118-128
39. Dudley ME, Gross CA, Somerville RP et al (2013) Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. J Clin Oncol 31:2152-2159
40. Knutson KL, Schiffman K, Cheever MA et al (2002) Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p 369-377, results in short-lived peptide-specific immunity. Clin Cancer Res 8:1014-1018
41. Klebanoff CA, Gattinoni L, Torabi-Parizi P et al (2005) Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci USA 102:9571-9576
42. Perret R, Ronchese F (2008) Memory T cells in cancer immunotherapy: which CD8 T-cell population provides the best protection against tumours? Tissue Antigens 72:187-194
43. Waight JD, Hu Q, Miller A, Liu S, Abrams SI (2011) Tumor-derived G-CSF facilitates neoplastic growth through a granulocytic myeloid-derived suppressor cell-dependent mechanism. PLoS ONE 6(11):e27690
44. Mundy-Bosse BL, Thornton LM, Yang HC et al (2011) Psychological stress is associated with altered levels of myeloid-derived suppressor cells in breast cancer patients. Cell Immunol 270:80-87
45. Moreno M, Molling JW, von Mensdorff-Pouilly S et al (2008) IFN-gamma-producing human invariant NKT cells promote tumor-associated antigen-specific cytotoxic T cell responses. J Immunol 181:2446-2454
46. Stober D, Jomantaite I, Schirmbeck R et al (2003) NKT cells provide help for dendritic cell-dependent priming of MHC class I-restricted CD8+ T cells in vivo. J Immunol 170:2540-2548
47. Hermans IF, Silk JD, Gileadi U et al (2003) NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J Immunol 171:5140-5147
48. Hegde S, Jankowska-Gan E, Roenneburg DA et al (2009) Human NKT cells promote monocyte differentiation into suppressive myeloid antigen-presenting cells. J Leukoc Biol 86:757-768
49. Zhang AL, Colmenero P, Purath U et al (2007) Natural killer cells trigger differentiation of monocytes into dendritic cells. Blood 110:2484-2493
50. Goldszmid RS, Caspar P, Rivollier A et al (2012) NK cell-derived interferon-gamma orchestrates cellular dynamics and the differentiation of monocytes into dendritic cells at the site of infection. Immunity 36:1047-1059
51. Gerosa F, Baldani-Guerra B, Nisii C et al (2002) Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med 195:327-333
52. Kuylenstierna C, Bjorkstrom NK, Andersson SK et al (2011) NKG2D performs two functions in invariant NKT cells: direct TCR-independent activation of NK-like cytolysis and co-stimulation of activation by CD1d. Eur J Immunol 41:1913-1923
53. Mamessier E, Sylvain A, Thibult ML et al (2011) Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest 121:3609-3622
54. Madjd Z, Spendlove I, Moss R et al (2007) Upregulation of MICA on high-grade invasive operable breast carcinoma. Cancer Immun 7:17
55. Barber A, Rynda A, Sentman CL (2009) Chimeric NKG2D expressing T cells eliminate immunosuppression and activate immunity within the ovarian tumor microenvironment. J Immunol 183:6939-6947
56. Spear P, Barber A, Rynda-Apple A et al (2012) Chimeric antigen receptor T cells shape myeloid cell function within the tumor microenvironment through IFN-gamma and GM-CSF. J Immunol 188:6389-6398
57. Zhou Z, Zhang C, Zhang J et al (2012) Macrophages help NK cells to attack tumor cells by stimulatory NKG2D ligand but protect themselves from NK killing by inhibitory ligand Qa-1. PLoS ONE 7:e36928
58. Parviz M, Chin CS, Graham LJ et al (2003) Successful adoptive immunotherapy with vaccine-sensitized T cells, despite no effect with vaccination alone in a weakly immunogenic tumor model. Cancer Immunol Immunother 52(12):739-750